Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01961128 · ClinicalTrials.gov registry record · NA

RPFNA Assessment of Exercise Effect in Breast Cancer

A NA study, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
2
Enrollment target

NCT01961128: Completed NA study, sponsored by Dana-Farber Cancer Institute.

NCT01961128 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01961128, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
2 participants
Enrollment target

Study Summary

This study is being done to see if the investigators can measure changes that occur in breast tissue when women at risk of developing breast cancer start an exercise program. The investigators are interested in studying this because research shows that women who exercise regularly are less likely to develop breast cancer, but there is not very much information explaining how exercise could affect breast cells in a way to prevent cancer from occurring. In this research study the investigators will use a research technique called breast random fine needle aspiration (RPFNA) to test breast cells for their shape and how they look. The investigators will look at breast cells before and after a participant takes part in an exercise program to see if the investigators are able to see any changes in breast cells that could have happened due to the exercise program. This research will help us to develop larger projects to see if exercise programs could be helpful in preventing breast cancer.

Primary Outcome

This is a small pilot feasability study designed to see if we can recruit patients into this kind of trial and if we can measure biomarker expression in breast tissue collected through RPFNA. Data analyses will be primarily descriptive in this pilot study. The primary feasibility endpoint will be assessed by the number of women with pre- and post-exercise RPFNA samples with sufficient cells (\> 500) for analysis. We require evidence that at least 60% of participants could provide adequate sampl

Interventions

  • BEHAVIORAL Exercise Intervention

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2011-10
Est. Completion 2014-03
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the finished NCT01961128 record still lists

NCT01961128 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).

The record links to 0 conditions, and to 1 intervention - of which Exercise Intervention is the first listed.

NCT01961128 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01961128 about?

NCT01961128 is a clinical study titled "RPFNA Assessment of Exercise Effect in Breast Cancer". This study is being done to see if the investigators can measure changes that occur in breast tissue when women at risk of developing breast cancer start an exercise program. The investigators are interested in studying this because research shows that women who exercise regularly are less likely to...

What is the current status of trial NCT01961128?

This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2011-10. Estimated completion is 2014-03.

What interventions are being tested in trial NCT01961128?

The interventions under investigation include: Exercise Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT01961128?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01961128's enrollment target sits among peer trials

2 1997th of 2000 the lowest of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01961128, the US trial registry maintained by the National Library of Medicine. NCT01961128 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.